What is Human Rotavirus Vaccine Market?
It is estimated that about 600,000 children die every year from rotavirus, with more than 80% of all rotavirus-related deaths occurring in resource-poor countries in south Asia and sub-Saharan Africa. Rotavirus infection is the most common cause of severe diarrhea disease in infants and young children around the globe and continues to have a major global impact on childhood morbidity and mortality. The human rotavirus vaccine is considered highly effective in preventing severe gastrointestinal disease. The human rotavirus vaccine is the only control measure likely to have a significant impact on the incidence of severe dehydrating rotavirus disease.
The market study is being classified by Type (Rotarix, Rotavac, Rotavin-M1, Lanzhou Lamb and Others), by Application (Hospitals, Clinics, Academic and Research and Others) and major geographies with country level break-up.
Merck & Co., Inc. (United States), Bharat Biotech International Limited (India), GlaxoSmithKline plc. (United Kingdom), Sanofi S.A. (France), Lanzhou Institute of Biologicals Products Co., Ltd (China), BIOVIRx Inc (United States), Serum Institute of India Pvt. Ltd. (India), Biological E (India) and Bio Farma (Indonesia) are some of the key players profiled in the study.
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Human Rotavirus Vaccine market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Human Rotavirus Vaccine market by Type, Application and Region.
On the basis of geography, the market of Human Rotavirus Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Prevalence of Rotavirus Infection
- Increased Number of Hospitals and Diagnostic Centres
- Rise in Healthcare Infrastructure among Developing Countries
- Increased Research and Development Investment
- Rise in the Government Initiatives
- Immune Reactions and Side Effects of Vaccine
- Growing Healthcare Industry Worldwide
- Increasing Demand from End-users
- Stringent Government Rules and Regulations
Key Target AudienceHuman Rotavirus Vaccine Manufacturers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase